August 23, 2018
Takeda Pharmaceutical and Ono Pharmaceutical said on August 22 that they will collaborate to carry out PIII development in Japan for a combination therapy of their cancer drugs Opdivo (nivolumab) and cabozantinib for the treatment of renal cell carcinoma (RCC)...read more